MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Hutchison China MediTech Ltd ADR

Slēgts

SektorsVeselības aprūpe

17.51 0.34

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.49

Max

17.6

Galvenie mērījumi

By Trading Economics

Ienākumi

6M

Pārdošana

162M

P/E

Sektora vidējais

81.15

39.857

Peļņas marža

3.676

Darbinieki

1,811

EBITDA

-5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+19.01% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

2.8B

Iepriekšējā atvēršanas cena

17.17

Iepriekšējā slēgšanas cena

17.51

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 18. jūl. 21:01 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 20:50 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 20:46 UTC

Peļņas

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025. g. 18. jūl. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 20:36 UTC

Peļņas

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025. g. 18. jūl. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025. g. 18. jūl. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 20:02 UTC

Tirgus saruna

Gold Higher to Close Out Week -- Market Talk

2025. g. 18. jūl. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025. g. 18. jūl. 19:06 UTC

Tirgus saruna

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025. g. 18. jūl. 18:24 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025. g. 18. jūl. 18:19 UTC

Peļņas

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025. g. 18. jūl. 18:11 UTC

Iegādes, apvienošanās, pārņemšana

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025. g. 18. jūl. 18:11 UTC

Peļņas

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025. g. 18. jūl. 17:35 UTC

Tirgus saruna

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025. g. 18. jūl. 16:29 UTC

Tirgus saruna

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025. g. 18. jūl. 16:28 UTC

Iegādes, apvienošanās, pārņemšana

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025. g. 18. jūl. 16:22 UTC

Peļņas

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Energy & Utilities Roundup: Market Talk

2025. g. 18. jūl. 16:20 UTC

Tirgus saruna
Peļņas

Basic Materials Roundup: Market Talk

2025. g. 18. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 18. jūl. 16:04 UTC

Peļņas

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 18. jūl. 15:58 UTC

Tirgus saruna

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025. g. 18. jūl. 15:47 UTC

Tirgus saruna
Peļņas

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Salīdzinājums

Cenas izmaiņa

Hutchison China MediTech Ltd ADR Prognoze

Cenas mērķis

By TipRanks

19.01% augšup

Prognoze 12 mēnešiem

Vidējais 20.85 USD  19.01%

Augstākais 27 USD

Zemākais 14.7 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Hutchison China MediTech Ltd ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

1

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

14.24 / 14.78Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.